ITGAM and glomerulonephritis: This has been recapitulated therapeutically in pre-clinical studies with the CD11b agonist leukadherin-1, which prevented kidney allograft rejection due to impaired leukocyte infiltration (45) and protected against glomerulonephritis in an induced injury model (46).